National Institute of Neurological Disorders and Stroke (NINDS)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Neurological Disorders and Stroke (NINDS) sits in the top decile of US sponsors by registered trial count (#61 of 15,742 sponsors by registered trial count).
National Institute of Neurological Disorders and Stroke (NINDS): 567 sponsored US clinical trials, 48 recruiting.
National Institute of Neurological Disorders and Stroke (NINDS) sponsors 567 registered US clinical trials on ClinicalTrials.gov, 48 of them currently recruiting, and 467 completed. 16 of these trials are in Phase 3-4 (later-stage) and 158 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 23 trials.
Top-decile sponsor footprint
National Institute of Neurological Disorders and Stroke (NINDS) ranks in the top decile of sponsors by registered trial count (#61 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
467 of 508 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
567 total, page 10 of 12
Physiologic Studies of Spasticity
NCT00014976
Amlodipine Plus Botulinum Toxin for Focal Dystonia
NCT00015457
Effects of Flumazenil on Brain Excitability
NCT00015678
Magnetic Resonance Imaging to Investigate Silent Strokes During Neck and Skull Angioplasty
NCT00015717
Riluzole to Treat Parkinson's Disease
NCT00013624
E-Selectin Nasal Spray to Prevent Stroke Recurrence
NCT00012454
Study and Surgical Treatment of Syringomyelia
NCT00011245
Rolipram to Treat Multiple Sclerosis
NCT00011375
EMD 128130 for the Treatment of Parkinson's Disease
NCT00009048
Ketogenic Diet in Lafora Disease
NCT00007124
Gluten-Free Diet in Patients With Gluten Sensitivity and Cerebellar Ataxia
NCT00006492
Study of Brain Changes Shaped by Experience
NCT00006424
KW-6002 to Treat Parkinson's Disease
NCT00006337
Hand Exercise and Upper Arm Anesthesia to Improvements Hand Function in Chronic Stroke Patients
NCT00006414
Sensory Training to Treat Focal Dystonia
NCT00006336
Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease
NCT00006077
Effect of Levetiracetam on Brain Excitability
NCT00006191
Brain Infusion of Muscimol to Treat Epilepsy
NCT00005925
Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy
NCT00005903
PET Scans in Normal Volunteers and Patients With Fabry Disease
NCT00005111
Study of Brain Activity During Speech Production and Speech Perception
NCT00004991
Electromyography to Diagnose Neuromuscular Disorders
NCT00004553
Gentamicin Treatment of Muscular Dystrophy
NCT00005574
Hypothermia During Intracranial Aneurysm Surgery Trial
NCT00029133
Study of LY300164 for the Treatment of Parkinson's Disease
NCT00004576
Positron Emission Tomography (PET) to Study Brain Signaling
NCT00044200
1-Octanol to Treat Essential Tremor
NCT00001986
Brain Imaging and Retreatment Study of Persistent Lyme Disease
NCT00037479
Blood Sampling for Neurochemical and Genetic Testing
NCT00001147
Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor
NCT00001148
Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turner's Syndrome
NCT00004275
Electrical Muscle Stimulation to Aid Swallowing in Dysphagia
NCT00001936
Zenapax to Treat Multiple Sclerosis
NCT00001934
Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes
NCT00004351
Nefiracetam in the Treatment of Alzheimer's Disease
NCT00001933
Serotonin Receptors in Seizure Disorders
NCT00001932
Treatment of Parkinson's Disease With a Transdermal Skin Patch
NCT00001931
The Connection Between Areas in the Brain of Blind Patients
NCT00001926
Treatment of Huntington's Chorea With Amantadine
NCT00001930
Treatment of Parkinson's Disease With Eliprodil
NCT00001929
Intravenous Levodopa for the Diagnosis of Parkinson's Disease
NCT00001928
Study of Abnormal Blood Clotting in Children With Stroke
NCT00001927
Study of Attention Deficit/Hyperactivity Disorder Using Transcranial Magnetic Stimulation
NCT00001915
Reduced Manipulation of the Aorta and Neurobehavioral Outcome Trial
NCT00059319
Theory-Based Interventions for Smoking and Obesity (Challenge) Trial
NCT00040287
Effect of Alcohol on Tremors
NCT00001925
Transcranial Magnetic Stimulation for the Treatment of Phantom Pain
NCT00001923
Sensory Function in Idiopathic Voice Disorders
NCT00001922
Efficacy of a Family Telephone Intervention for Stroke
NCT00031265
Parkinson's Disease Treatment With Coenzyme Q10
NCT00004731
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 80 |
| Phase 2 | 78 |
| Phase 3 | 11 |
| Phase 4 | 5 |
Therapeutic Areas
What is open in the National Institute of Neurological Disorders and Stroke (NINDS) pipeline
48 recruiting of 567 indexed (8% open); 467 completed (82%).
Phase mix: 16 late (III/IV) vs 158 early (I/II) (early-phase heavy).
Top condition: Healthy (23 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Neurological Disorders and Stroke (NINDS): open-pipeline peers nationwide
Peers matched on 567 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Neurological Disorders and Stroke (NINDS) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 567 trials (± recruiting share)
- Children's Hospital Medical Center, Cincinnati · 571 trials · 19% recruiting
- University of Maryland, Baltimore · 560 trials · 18% recruiting
- Amgen · 558 trials · 10% recruiting
- Merck Sharp & Dohme · 558 trials · 22% recruiting
Sponsors near 8% open enrollment (± trial volume)
- National Jewish Health · 8% recruiting · 83 trials
- ACADIA Pharmaceuticals · 9% recruiting · 35 trials
- Texas Tech University Health Sciences Center, El Paso · 9% recruiting · 35 trials
- Boehringer Ingelheim · 8% recruiting · 515 trials
Related
What to do with this National Institute of Neurological Disorders and Stroke (NINDS) page
567 registered trials is a research-attention snapshot, not an endorsement of National Institute of Neurological Disorders and Stroke (NINDS) or any single study.
- 48 of National Institute of Neurological Disorders and Stroke (NINDS)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition National Institute of Neurological Disorders and Stroke (NINDS) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Neurological Disorders and Stroke (NINDS) pipeline card: 567 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.